Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Calls For Pre-Market CV Safety Trials For Some Constipation Drugs

This article was originally published in The Pink Sheet Daily

Executive Summary

Serotonin receptor 4 agonists for use in constipation have been in limbo due to potential for CV risk; FDA is seeking recommendations about safety studies for the class from an advisory committee.

You may also be interested in...



The New Zelnorm-al (Part 2): More Thoughts On The Revival Of The 5HT4 Class

Looming return of Zelnorm to US market is milestone event for current regulatory climate. But FDA’s hands-on work to resurrect a different 5HT4 agonist, prucalopride, probably says more about what is truly different about the agency today.

VC-backed GI Start-Ups See Opportunity In IBS

Private companies developing drugs for gastrointestinal disorders such as inflammatory bowel disease and irritable bowel syndrome hope to take advantage of a resurging interest in the space after linaclotide developer Ironwood Pharmaceuticals has shown its novel, locally acting guanylate cyclise type-C agonist is efficacious in four Phase III trials. We profile four such hopefuls in this issue: Altheus Therapeutics, AltheRx Pharmaceuticals, Aldrex and Second Genome.

GI Drugs Cmte. To Weigh Retreatment Study Design For Salix's Xifaxan In Irritable Bowel

On Nov. 16, FDA's outside advisors will discuss the design of clinical trials to evaluate the safety, efficacy and durability of response with repeat treatment cycles of rifaximin for diarrhea-predominant IBS.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS072814

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel